Biotech Values

[floblu14]

MNTA's Current U.S. and European Patent Applications -

1. NUCLEOTIDE CLONING METHODS 2014-12-11

Methods of cloning insert sequences into cloning vectors with high efficiency and in the correct orientation are described. In one aspect, the invention features a method of producing a plasmid comprising an insert fragment and a vector fragment in a predetermined orientation. In some embodiments, the method includes cleaving a first nucleotide sequence at a plurality of sites with a first restriction enzyme to generate a first population of nucleotide fragments, the first population of nucleotide fragments comprising insert fragments and non-insert fragments, the insert fragments comprising a non-palindromic overhang at a 5' end, at a 3' end, or at both.

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20141211&CC=US&NR=2014363853A1&KC=A1

2. PHARMACEUTICAL COMPOSITIONS COMPRISING PYROPHOSPHATE
2014-12-04

Described herein are therapeutic compositions comprising a therapeutic agent and pyrophosphate.

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=1&ND=3&adjacent=true&locale=en_EP&FT=D&date=20141204&CC=WO&NR=2014193821A1&KC=A1

3. PHARMACEUTICAL COMPOSITIONS 2014-12-04

Described herein are pharmaceutical compositions comprising a LMWH preparation having at least one chain having a glycol split uronic acid residue (UG) in the preparation and uses thereof.

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=2&ND=3&adjacent=true&locale=en_EP&FT=D&date=20141204&CC=WO&NR=2014193818A1&KC=A1

4. CONTROL OF COPOLYMER COMPOSITIONS 2014-12-01

Methods of making copolymers are described.

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=3&ND=3&adjacent=true&locale=en_EP&FT=D&date=20141201&CC=ES&NR=2523732T3&KC=T3


5. METHODS FOR THE TREATMENT OF NEURODEGENERATION
2014-11-20

The invention encompasses the discovery that Fc-containing polypeptides that include branched glycans and that are sialylated on the branched glycan (e.g., on an [alpha] 1,3 and/or [alpha] 1,6 arm in the Fc region's N-linked glycosylation site), with, e.g., a NeuAc-[alpha] 2,6-Gal or NeuAc-[alpha] 2,3-Gal terminal linkage, are useful in treating neurodegeneration, e.g., in the treatment of neurodegenerative diseases such as Alzheimer's Disease. The present disclosure provides, in part, methods for treating neurodegeneration or neurodegenerative diseases by administering compositions containing such Fc-containing polypeptides as well as methods for evaluating, identifying, and/or producing (e.g., manufacturing) such polypeptides for the treatment of neurodegeneration

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=4&ND=3&adjacent=true&locale=en_EP&FT=D&date=20141120&CC=WO&NR=2014186310A1&KC=A1

6. METHODS RELATED TO CELL SURFACE GLYCOSYLATION
2014-11-11

The present disclosure provides methods for assessing the glycosylation of a target glycoprotein produced by a cell through analysis of cell-surface glycans on the cell. The present disclosure therefore teaches that glycosylation of cell surface proteins can serve as a proxy for glycosylation of other proteins.

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=5&ND=3&adjacent=true&locale=en_EP&FT=D&date=20141111&CC=BR&NR=PI0810472A2&KC=A2

7. DEFINED GLYCOPROTEIN PRODUCTS AND RELATED METHODS
2014-11-11

Abstract not available.

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=6&ND=3&adjacent=true&locale=en_EP&FT=D&date=20141111&CC=BR&NR=PI0810471A2&KC=A2

8. SIALYLATED GLYCOPROTEINS 2014-11-6

Glycoproteins having particular sialylation patterns, and methods of making and using such glycoproteins, are described.

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=7&ND=3&adjacent=true&locale=en_EP&FT=D&date=20141106&CC=WO&NR=2014179601A2&KC=A2

Patents

We license or own a patent portfolio of over 70 patent families, each of which includes United States patent applications and/or issued patents as well as foreign counterparts to certain United States patents and patent applications. Our patent portfolio includes issued or pending claims covering:

*Methods and technologies for characterizing polysaccharides and other heterogeneous mixtures

*The composition of matter and use of certain heparinases, heparinase variants and other enzymes

*Methods and technologies for synthesis of polysaccharides

*The composition of matter and use of certain novel low molecular weight heparin products, including M402

*Methods to identify, analyze and characterize glycoproteins

*Methods of manufacture of certain polysaccharide, polypeptide and complex protein or biologic products

http://www.momentapharma.com/technology/patents.php